Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: Response assessment and imaging biomarkers

Future Oncology

Volumn 12, Issue 3, 2016, Pages 333-342

  Maines, Francesca ^a   Caffo, Orazio ^a   Donner, Davide ^a   Sperduti, Isabella ^b   Bria, Emilio ^c   Veccia, Antonello ^a   Chierichetti, Franca ^a   Tortora, Giampaolo ^c   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

18F choline PET; castration resistant prostate cancer; enzalutamide; response

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; DOCETAXEL; ENZALUTAMIDE; FLUORINE 18; ANTINEOPLASTIC AGENT; FLUOROMETHYLCHOLINE; PHENYLTHIOHYDANTOIN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MALE; METABOLIC PARAMETERS; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; TISSUE DISTRIBUTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BONE NEOPLASMS; CHOLINE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENYLTHIOHYDANTOIN; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84956482229     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.277     Document Type: Article

References (34)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of United States, National cancer institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009
3. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47(1), 207-214 (1981
4. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am. J. Roentgenol. 198(4), 737-745 (2012
5. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009
6. Van den Abbeele AD. The lessons of GIST: PET and PET/CT-a new paradigm for imaging. Oncologist 13(Suppl. 2), 8-13 (2008
7. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol. 31(5), 578-583 (2000
8. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007
9. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am. J. Roentgenol. 194(6), 1470-1478 (2010
10. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am. J. Roentgenol. 194(1), 157-165 (2010
11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl. 1), S122-S150 (2009
12. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 15(1), 45-55 (2012
13. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012
14. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424-433 (2014
15. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol. 26(7), 1148-1159 (2008
16. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organisation for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35(13), 1773-1782 (1999
17. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 32(6), 668-673 (2005
18. Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur. J. Nucl. Med. Mol. Imaging 32(6), 660-667 (2005
19. Jadvar H, Desai B, Ji L, et al. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J. Nucl. Med. 54(8), 1195-1201 (2013
20. Meirelles GS, Schoder H, Ravizzini GC, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTC-MDP bone scan in progressing prostate cancer. Clin. Cancer Res. 16(24), 6093-6099 (2010
21. Halabi S, Armstrong AJ, Sartor O, et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J. Clin. Oncol. 31(31), 3944-3950 (2013
22. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011
23. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010
24. Beheshti M, Imamovic L, Broinger G, et al. 18F-choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3), 925-933 (2010
25. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur. J. Nucl. Med. Mol. Imaging 33(12), 1387-1398 (2006
26. Pelosi E, Arena V, Skanjeti A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol. Med. 113(6), 895-904 (2008
27. Pinkawa M, Attieh C, Piroth MD, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18F-choline PET/CT detected simultaneous integrated boost. Radiother. Oncol. 93(2), 213-219 (2009
28. Giovacchini G, Picchio M, Coradeschi E, et al. [11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur. J. Nucl. Med. Mol. Imaging 35(6), 1065-1073 (2008
29. Challapalli A, Barwick T, Tomasi G, et al. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. Nucl. Med. Commun. 35(1), 20-29 (2014
30. Fuccio C, Schiavina R, Castellucci P, et al. Androgen deprivation therapy influences the uptake of 11C-cholinein patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur. J. Nucl. Med. Mol. Imaging 38(11), 1985-1989 (2011
31. Ceci F, Schiavina R, Castellucci P, et al. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT. Clin. Nucl. Med. 38(7), e279-e282 (2013
32. De Giorgi U, Caroli P, Burgio SL, et al. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 5(23), 12448-12458 (2014
33. De Giorgi U, Caroli P, Scarpi E, et al. (18) F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur. J. Nucl. Med. Mol. Imaging 42(8), 1276-1283 (2015
34. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 17(14), 4854-4861 (2011